Blutgerinnung und Sexualsteroide

Ist der Gestagenbeitrag zum Thromboserisiko plausibel?
Prof. Dr. med. Ludwig Wildt; Seiten 6–9

  1. Vessey MP., Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BrMedJ (1968) 2:199-205
  2. Birkhäuser. Hormonelle Kontrazeptiva der zweiten, dritten und vierten Generation. Gynäkologische Endokrinologie (2010);1-7
  3. No authors listed. Effect of different progesteros in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organizitation Collaborative Study of Cardiovascula Disease and Steroid Hormone Contraception. Lancet (1995) 346; 1582-1588
  4. Lidegaard Ø, LØkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ (2009) 339: b2890; 1-8
  5. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogens dose and progestogen type: Results of the MEGA case-control study. BMJ (2009) 339: b2921
  6. Blanco-Molina A., Monreal M. Venous thromboembolism in women taking hormonal contraceptives. Expert Rev. Cardiovasc. Ther. (2010) 8 (2); 211-215
  7. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: Review of two recently published studies. J Fam Plann Reprod Health Care (2010) 36 (1): 33-38
  8. Heinemann LAJ, Dinger JC, Assmann A, Do Minh Thai. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: Outlook 10 years after the third-generation “pill scare”. Contraception 81 (2010): 401-40
  9. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared witz women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ (2011) 342: d2151
  10. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or Levonorgestrel: nested case-control study based on UK general practice research database. BMJ (2011) 342: d2139
  11. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E: Risk of venous thromboembolism from use of oral contraceptives containig different progestogens and oestrogen doses:Danish cohort study from 2001 to 2009. British Medical Journal 343 (2011). Epub ahead of print
  12. Martinez F., Ramirez I, Perez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis.  EurJ Contracept Reprod Health Care (2012) Feb 17(1): 7-29
  13. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives basen on 142.475 Women-Years of observation. Contraception (2007) 75(5): 344-54
  14. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception. (2007) 75(5):326-36
  15. Lidegaard O, Nielsen LH,. Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal conception: follow-up study, Denmark 2001-10. BMJ (2012) 344: e2990
  16. Lidegaard Ø, LØkkegaard E, Jensen A., Skovlund Wessel C., Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med (2012) 366:2257-66
  17. Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J. Effiacacy and safety of a novel oral contraceptive based on östradiol (oestradiol valerate/dionegest): A Phase III trial. Eur J Obstet Gynecol Reprod Biol (2010) 149:57-62
  18. Kiley JW, Shulman LP. Estradiol valerate and Dienogest: A new approach to oral contraception. Int. J. Womens Health (2011) 3: 281-286
  19. van Diepen HA. Preclinical pharmacological profile of nomegestrol acetate, A synthetic 19-nor-progesterone derivative. Reprod Biol Endocrinol. (2012) Oct 8;10 (1):85
  20. Yan LP, Plosker GL. Nomegestrol acetate/Estradiol: in oral contraception. Drugs. (2012) Oct 1; 72 (14):1917-28
  21. Sordal T, Gro P, Verhoeven C. Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17?-estradiol in comparison to Levonorgestrel/Ethinylestradiol. Acta Obstet Gynecol Scand. (2012) Nov 91 (11):1279-85
  22. Westhoff C, Kaunitz AM, Korver T, Sommer W, Bahamondes L, Damey P, Verhoeven C. Efficacy, sefety, and telerability of a monophasic oral contraceptive containing nomegestrol acetate and 17?-estradiol: a randomized controlled trial. Obstet Gynecol. (2012) May;119 (5): 989-99

Update Notfallkontrazeption

Wenn Ihre Patientin „in Nöten” ist
Gemeinsame Stellungnahme der DGGEF e.V. und des BVF e.V.; Prof. Dr. med. Dr. med. h.c. Thomas Rabe  und Dr. med. Christian Albring zusammen mit dem Arbeitskreis „Postkoitale Kontrazeption“
Seiten 10-14

  1. Smith CL, O´Malley, BW. Coregular function: A key to understanding tissue specifity of selective receptor modulators. Endocr Rev. (2004) 25(1): 45-71
  2. Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Croxatto HB. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. (2010) Sep;25(9):2256-63. doi: 10.1093/humrep/deq157. Epub 2010 Jul 15
  3. Trussel J, Rodriquesz G, Ellerston C. new estimates of the effectiveness of the Yuzpe regimen or emergency contraception. Contraception (1998) 57 (6): 363-9
  4. International Federation of Gynecology and Obstetrics (FIGO) and International Consortium for Emergency Contraception (ICEC) (April 4, 2011). Mechanism of action: How do levonorgestrel-only emergency contraceptive pills (LNG ECPs) prevent pregnancy? London: International Federation of Gynecology and Obstetrics
  5. Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Croxatto HB. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. (2010) Sep;25(9):2256-63. doi: 10.1093/humrep/deq157. Epub 2010 Jul 15.
  6. Hermann Behre, Eberhard Nieschlag (2000). Andrology : Male Reproductive Health and Dysfunction. Berlin: Springer. ISBN 3-540-67224-9
  7. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Ulipristal acetate versus levonorgestrel for emergency contraception: A randomised non-inferiority trial and meta-analysis. Lancet (2010) 13: 555–62
  8. Gemzell-Danielsson K, Berger C, P G L L. Emergency contraception - mechanisms of action. Contraception (2012) Oct 29. pii: S0010-7824(12)00750-0. doi: 10.1016/j.contraception.2012.08.021. [Epub ahead of print]
  9. www.who.int/mediacentre/factsheets/fs244/en/index.html
  10. Halstrick C. Juristische Aspekte der Mädchen-Sprechstunde: Der Behandlungsvertrag. Frauenarzt (2005a) 46(7): 581-585
  11. Halstrick C. Juristische Aspekte der Mädchen-Sprechstunde: Verordnung von Kontrazeptiva. Frauenarzt (2005b) 46(8): 660-663
  12. Halstrick C: Mädchen-Sprechstunde. Juristische Aspekte in der Mädchen-Sprechstunde. Rechtliche Fragen bei der Behandlung Minderjähriger in der frauenärztlichen Praxis. Teil 1: Der Behandlungsvertrag. Frauenarzt 52 (2011a) 1110-1114
  13. Halstrick C: Mädchen-Sprechstunde. Juristische Aspekte in der Mädchen-Sprechstunde. Rechtliche Fragen bei der Behandlung Minderjähriger in der frauenärztlichen Praxis. Teil 2: Ärztliche Schweigepflicht bei Minderjährigen, häufi-ge Behand¬lungssituationen in der Frauenarztpraxis. Frauenarzt 52 (2011) 1224-1229

korasion 2/2013: Rezidivierende Vulvasynechien

Differenzierte Therapieoptionen
Dr. med. Nikolaus Weissenrieder und Dr. med. Eva-Maria Lochmüller
Seiten 19–26

  1. 1. Bacon JL; Prepubertal labial adhesions: evaluation of a referral pupulation; Am J Obstet Gynecol (2002) 187: 327-331
  2. Caparo VJ,Greenburg H; The Incidence of labial confusion in children; Obstet. Gynecolog (1972) 39: 65-69
  3. Davis VJ, Coates M; Success of medical management of labial adhesions; J Pediatr adolesc Gynecol (2001) 14:142-145
  4. Kunmetz LM,Quint EH, Fisseha S, Smith YR; Estrogen treament in recurrent and persistent labial agglutination; J Pediatr Adoles Gynecol (2006) 19: 381-384
  5. Leung AK, Robson WL,Tay-Uyboco J; The incidence of labial confusion in children. J paediatr Child Health (1993) 29: 235-237
  6. Myers,JB,Sorensen CM,Wisner BP,Furness PD; Betamethasone cream for the treatment of prpubertal labial adhesions. J.Pediatr. Adolesc Gynecol (2006) 19: 407-411
  7. Schober J, Dulabon L, Martin-AlguacilN; Significance of topical estrgens to labial Fusion and vaginal introital integrity; J Pediatr Adoles Gynecol (2006) 19: 337-339
  8. Van Eyk N,Allen L, Giesbrecht E, e.a.; Pediatric Vulvovaginal Disorders: A Diagnostic Approach and Review of the Literature. J Obstet Gynaecol Can (2009) 31(9): 850-862
  9. Velander MH, Mikkelsen DB, Bygum A; Labial Agglutination in a Prepubertal Girl: Effect of Topical Oestrogen; Acta Dermato-Venereologica (2009) 89: 198-199

Trendthema: „Runner’s Amenorrhö“

Die Rolle der Zyklusphasen im Training der Frau
Dr. med. Ursula Hildebrandt
Seiten 28-30

  1. Roepstorff, C. et al. 2006. Sex differences in hormone-sensitive lipase expression, activity, and phosphorylation in skeletal muscle at rest and during exercise. In: Am J Physiol Endocrinol Metab, 291: E1106-E114
  2. Deutscher Schwimm-Verband e.V. 2011; Weber, J. 2007. Rekordversuch im eiskalten Ärmelkanal. In Welt online.
  3. Kindermann, W. 2000. Das Sportherz. In: Deutsche Zeitschrift für Sportmedizin, 51 (9): (307-308)
  4. De Marées, H. 2003. Sportphysiologie (9. Aufl.). Köln: Sportverlag Strauss
  5. Aspenes, S. T., et al, 2011. Medicine & Science in Sports & Exercise, 43 (8): 1457-1464
  6. Sandbakk Ø. et al. 2011. European J of Applied Physiology, 111 (7)
    10. Riddell et al. 2003. Int J of Sport Nutrition and Exercise Metabolism, 13 (4): 407-421
  7. Sartorio et al. 2004. J of Endocrinological Investigation, 27: 121-129
  8. Ilhan et al. 2004. Archives of Medical Research, 35, 294-300
  9. Wise et al. 2002. Pain, 96: 335-342
  10. Perreault et al. 2004. Obesity Research, 12: 241-249
  11. Weineck, J. 2010. Sportbiologie (10. Aufl.). Balingen: Spitta Verlag GmbH & Co. KG
  12. Hollmann/Strüder, 2009. Sportmedizin. Grundlagen für körperliche   Aktivität, Training und Präventivmedizin. Stuttgart: Schattauer GmbH
  13. Platen, P. 2008. Rubin, April, 104, 6-11
  14. Han A. Effects of menstrual cycle based-training on physiologic measures of endurance capacity and on muscle cell parameters in women with and without oral contraception. 2012. http://www-brs.ub.ruhr-uni-bochum.de/netahtml/HSS/Diss/HanAhreum/
  15. Sung E. Effects of menstrual cycle based-training on muscle strength, muscle volume and muscle cell parameters in women with and without oral contraception. 2012. http://www-brs.ub.ruhr-uni-bochum.de/netahtml/HSS/Diss/SungEunsook/diss.pdf
  16. Midwifery, J. 2006. Womens Health; 51(3): 193-201
  17. Mc Ardle WD et al. 2010. Exercise Physilogy. Nutrition, energy and human performance (7th Edition)
  18. Mastorakos G et al. 2005. Exercise and the Stress System. In: Hormones (Athens), 4(2): 73-89
  19. Petit/Prior, 2000. Exercise and hypothalamus. In: M. P. Waren et al. Contemporary Endocrinology: Sports Endocrinology. New Jersey: Humana Press, 142
  20. Kakanis MW, Peake J, Brenu EW, Simmonds M, Gray B, Hooper SL, Marshall-Gradisnik SM. The open window of susceptibility to infection after acute exercise in healthy young male elite athletes. Exerc Immunol Rev. 2010; 16:119-37
  21. Pedersen B and Bruunsgaard H. 1995. How physical exercise influences the establishment of infection. Sports  Med 19: 393-400
  22. Roupas, 2011. Menstrual function in sports. In: HORMONES, 10(2):104-116
  23. Artal R: Exercise: the alternative therapeutic intervention for gestational diabetes. Clin Obstet Gynecol 46 (2003) 479-487
  24. Brankston GN, Mitchell BF, Ryan EA, Okun NB: Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. Am J Obstet Gynecol 190 (2004) 188-193
  25. Artal R und O'Toole M. 2003. Guidelines of the American College of Obstetricians and Gynecologists for exercise during pregnancy and the postpartum period. Br J Sports Med 37; 6-12
  26. Clapp JF. 2000. Exercise during pregnancy. A clinical update. Clin Sports Med 19; 273-286
  27. Kagan KO und Kuhn U: Sports and pregnancy. Herz 29 (2004) 426-434
  28. American College of Obsttricians and Gynecologists: COG Committee Opinion. Exercise during pregnancy and the postpartum period. Int J Gynaecol Obstet (2002) 79-81
  29. Korsten-Reck U, Marquardt K, Wurster KG. Schwangerschaft und Sport. Deutsche Zeitschrift für Sportmedizin, Jahrgang 60, Nr. 5 (2009): 117-121
  30. Adamsen L, Quist M, Andersen C, Møller T, Herrstedt J, Kronborg D, Baadsgaard MT, Vistisen K, Midtgaard J, Christiansen B, Stage M, Kronborg MT, Rørth M. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009 Oct 13;339: b3410
  31. Basen-Engquist K, Taylor CL, Rosenblum C, Smith MA, Shinn EH, Greisinger A, Gregg X, Massey P, Valero V, Rivera E. 2004. Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient Educ Couns, Dec 64(1-3):225-34
  32. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K, Yasui Y, McKenzie DC. 2007. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. Oct 1;25(28):4396-404; Epub 2007 Sep 4
  33. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 2007 May 1;25 (13):1713-21
  34. Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol. 2005 Apr 98 (4):1534-40
  35. Rösner M. Evaluation eines Nordic-Walking-Programms bei Mammakarzinom-Patientinnen. Deutsche Zeitschrift für Sportmedizin, Jahrgang 62, Nr. 5 (2011): 120-124
  36. Heuke A. Einfluss einer sechswöchigen Wanderung auf brustkrebsspezifische Symptome. Bachelorarbeit an der DSHS Köln.

Hormonale Kontrazeption – Blutungsstörungen (Teil 2): Kontrazeptive Methoden und Blutungsmanagement

Gemeinsame Stellungnahme der DGGEF e.V. und des BVF e.V. (Prof. Dr. med. Dr. med. h.c. Thomas Rabe federführend) und des Arbeitskreises „Blutungsstörungen bei der Frau“
Seiten 40-45

  1. Salamonsen LA, Woolley DE: Matrix metalloproteinases in normal menstruation. Hum Reprod (1996) 11: 124-133
  2. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, Jaffe RB, and Taylor RN. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 81 (1996): 3112-3118
  3. Lockwood CJ, Schatz F, Krikun G. Angiogenic factors and the endometrium following long term progestin only contraception. Histol Histopathol (2004) 19:167-172
  4. Greb RR, Heikinheimo O, Willimas RF, Hodgen GD, Goodman AL. Hum Reprod (1997) 12:1280-1292
  5. Lockwood CJ, Krikun G, Hausknecht VA et al. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stroma cells during progestin-initiated decidualization and menstrualrelated progestin withdrawal. Endocrinology (1998) 139: 4607–4613
  6. Salamonsen LA, Zhang J, Hampton A et al. Regulation of matrix metalloproteinases in human endometrium. Hum Reprod 15 (2000) (suppl 3): 112–119
  7. Schatz F, Papp C, Aignew S et al. Biological mechanism undelying the clinical effects of RU486: Modulation of cultured endometrial stromal cell stromelysin-I and prolactin expression. J Clin Endocrinol Metab 82 (1997): 188–193
  8. Kuhl Herbert (2001) Neue Gestagene – ihre Vor- und Nachteile Therapeutische Umschau; Verlag Hans Huber, Bern; Band 58
  9. Kitawaki JO, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K, Honji H. Progesterone induction of 17?-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium, The Journal of clinical endocrinology and metabolism, 85 (2000) 3292-3296
  10. Hickey M, Dwarte D, Fraser IS. The endometrial vascular appearance in Norplant users: Preliminary results from an hysteroscopic study. Hum Reprod 11 (1996): 35–44
  11. Johannisson E, Brosens I, Cornillie F et al. Morphometric study of human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days. Contraception 43 (1991) 361–373
  12. Markee JE: Menstruation in intraocular endometrial transplants in the rhesus monkey. In: Contributions to embryology. Washington: Carnegie Institute of Washington (1940) Publication No. 518, 28: 219–308
  13. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod (2001)16:1527–1535
  14. Hickey M, Fraser I, Dwarte D, Graham S. Endometrial vasculature in Norplant users: Preliminary results from a hysteroscopic study. Hum Reprod (1996) 11(Suppl 2): 35–44
  15. Rodriguez-Manzaneque JC, Graubert M, Iruela-Arispe ML. Endothelial cell dysfunction following prolonged activation of progesterone receptor. Hum Reprod (2000) 15 (Suppl 3): 39–47
  16. Lockwood CJ, Runic R, Wan L, Krikun G, Demopolous R, Schatz F. The role of tissue factor in regulating endometrial haemostsis: Implications for progestin-only contraception. Hum Reprod (2000) 15 (Suppl 3): 144–151
  17. Clark DA, Wang S, Rogers P, Vince G, Affandi B. Endometrial lymphoid cells due to levonorgestrel (Norplant). Hum Reprod (1996) 11:1438–1444
  18. Livingston M, Fraser IS. Mechanismen of abnormal uterine bleeding. Human Reprod Update (2002) 8: 60-67
  19. Hickey M, d’Arcangues C. Vaginal bleeding disturbances and implantable contraceptives Contraception 65 (2002): 75–84
  20. Mansour D, Korver T, Marintcheva-Petrova M and Fraser IS. The effects of Implanon on menstrual bleeding patterns Europ J Contracept and Reproduc Health Care (2008) 13: 13-28
  21. Smith SK. Steroids and endometrial breakthrough bleeding: future directions for research. Hum Reprod (2000) 15 (Suppl 3): 197–202
  22. Lockwood CJ, Paidas M, Murk WK, Kayisli UA, Gopinath A, Huang SJ, Krikun G, Schatz F. Involvement of human decidual cell-expressed tissue factor in uterine hemostasis and abruption. Thromb Res. (2009) Nov;124 (5): 516-20. Epub 2009 Aug 31. Review.
  23. Rogers PA, Au CL, Affandi B. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod. (1993) Sep;8(9):1396-404
  24. Hickey M, Dwarte D, Fraser IS: The endometrial vascular appearance in Norplant users: preliminary results from an hysteroscopic study. Hum Reprod 11 (1996) 35–44
  25. Hickey M, Dwarte D, Fraser IS: Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod 13 (1998) 3190–3196
  26. Hickey M, Simbar M, Markham R et al. Changes in endothelial cell basement membrane in Norplant users. Hum Reprod 14 (1999a) 716–721
  27. Hickey M, Simbar M, Markham R et al.: Changes in endometrial vascular density in Norplant users. Contraception 59 (1999) 123–129
  28. Manconi F, Markham R, Cox G et al. Computergenerated, three-dimensional reconstruction of histological parallel serial sections displaying microvascular and glandular structures in human endometrium. Micron 32 (2001) 449–453
  29. Lau TM, Affandi B, Rogers PA: The effects of levonorgestrel implants on vascular endothelial growth factor statement in the endometrium. Mol Hum Reprod 5 (1999) 57–63
  30. Markee JE: Menstruation in intraocular endometrial transplants in the rhesus monkey. In: Contributions to embryology. Washington: Carnegie Institute of Washington (1940) Publication No. 518, 28:219–308
  31. Lau TM, Affandi B, Rogers PA: The effects of levonorgestrel implants on vascular endothelial growth factor statement in the endometrium. Mol Hum Reprod 5 (1999) 57–63
  32. Chwalisz C, Garfield RE: Role of nitric oxide in implantation and menstruation. Hum Reprod 15 (2000) (suppl 3) 96–111
  33. Hickey M, Dwarte D, Fraser IS: Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod 13 (1998) 3190–3196
  34. Lockwood CJ, Runic R, Wan L et al.: The role of tissue factor in regulating endometrial haemostasis: implications for progestin- only contraception. Hum Reprod 15 (2000) (suppl 3) 144–151
  35. Finn CA, Pope M: Vascular and cellular changes in the decidualized endometrium of the ovariectomized mouse following cessation of hormone treatment: a possible model for menstruation. Endocrinol 100 (1984) 295–300
  36. Salamonsen LA, Lathbury L: Endometrial leukocytes and menstruation. Hum Reprod Update 6 (2000) 16–27
  37. Salamonsen LA, Zhang J, Hampton A et al. Regulation of matrix metalloproteinases in human endometrium. Hum Reprod 15 (2000) (suppl 3) 112–119
  38. Hickey M, Simbar M, Markham R et al.: Changes in endothelial cell basement membrane in Norplant users. Hum Reprod 14 (1999a) 716–721
  39. Hickey M, Simbar M, Markham R et al.: Changes in endometrial vascular density in Norplant users. Contraception 59 (1999) 123–129
  40. Fraser IS, McCarron G, Hutton B et al. Endometrial blood flow measured by xenon-133 clearance in women with normal menstrual cycles and dysfunctional uterine bleeding. Am J Obstet Gynecol 156 (1987) 158–166
  41. Hickey M, Carati C, Manconi F et al. The measurement of endometrial perfusion in Norplant users: a pilot study. Hum Reprod 15 (2000) 1086–1091
  42. Burton KA, Henderson Ta, Hiller SG et al.: Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium. Hum Reprod 18 (2003) 2610–2617
  43. Lau TM, Witjaksono J, Affandi B et al. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users. Hum Reprod 11 (1996) 2629–2634
  44. Hickey M, Fraser I, Dwarte D, Graham S. Endometrial vasculature in Norplant users: preliminary results from a hysteroscopic study. Hum Reprod (1996)11 (Suppl 2): 35–44
  45. Song JY, Markham R, Russell P, Wong T, Young L, Fraser IS. The effect of highdose medium- and long-term progestogen exposure on endometrial vessels. Hum Reprod (1995)10:797–800
  46. Hickey M, Dwarte D, Fraser IS. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod (2000)15:1509–1514
  47. Hickey M, Dwarte D, Fraser IS: Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod 13 (1998) 3190–3196
  48. Hickey M, Simbar M, Markham R et al.: Changes in endothelial cell basement membrane in Norplant users. Hum Reprod 14 (1999a) 716–721
  49. Hickey M, Simbar M, Markham R et al.: Changes in endometrial vascular density in Norplant users. Contraception 59 (1999b) 123–129
  50. Lockwood CJ, Runic R, Wan L et al.: The role of tissue factor in regulating endometrial haemostasis: implications for progestin- only contraception. Hum Reprod 15 (2000) (suppl 3) 144–151
  51. Rogers PAW, Plunkett D, Affandi B: Perivascular smooth muscle actin is reduced in the endometrium of women with progestin- only contraceptive breakthrough bleeding. Hum Reprod 15 (2000) (suppl 3) 78–84
  52. Rodriguez-Manzaneque JC, Graubert M, Iruela-Arispe ML: Endothelial cell dysfunction following prolonged activation of progesterone receptor. Hum Reprod 15 (2000) (suppl 3) 39–47
  53. Critchley HOD, Wang H, Kelly RW et al.: Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrelreleasing intrauterine system. Human Reprod 13 (1998) 1210–1217
  54. Mustonen MV, Isomaa VV, Vaskivuo T et al.: Human 17ß-hydroxysteroiddehydrogenase typ 2 messenger ribonucleic acid expression and localisation in term placenta and in endometrium during menstrual cycle. J Clin Endocrinol Metab 83 (1998) 1319–1324
  55. Critchley HOD, Kelly RW, Baird DT et al. Regulation of human endometrial function:Mmechanisms relevant to uterine bleeding. Reproductive Biology and Endocrinology 4 (2006) (Suppl 1) 1–9
  56. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW: Selectivity in progesterone and androgen receptor binding of prostagens used in oral contraceptives. Contraception 38 (1988) 325–332
  57. Lemus AE, Vilchis F, Damsky R et al.: Mechanism of action of levonorgestrel: in vitro metabolism and specific interactions with steroid receptors in target organs. J Steroid Biochem Mol Biol 41 (1992) 881–890
  58. Critchley HOD, Wang H, Kelly RW et al.: Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrelreleasing intrauterine system. Human Reprod 13 (1998) 1210–1217
  59. Slayden OD, Mah K, Brenner RM: A critical oeriod of progesterone withdrawel exists for endometrial MMPs and menstruation in macaques. Biol Reprod 60 (1999) 273
  60. Guttinger A, Critchley. HOD Contraception (2007) 75: 93-98
  61. Burton KA, Henderson Ta, Hiller SG et al.: Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium. Hum Reprod 18 (2003) 2610–2617
  62. Smith SK: Regulation of engiogenesis in the endometrium. Trends Endocrinol Metab 12 (2001) 147-151
  63. Hickey M, d’Arcangues C. Vaginal bleeding disturbances and implantable contraceptives Contraception 65 (2002) 75–84
  64. Vincent AJ, Salamonsen LA: MMP, leucocytes and steroid-associated uterine bleeding. Hum Reprod 15 (2000) 135–144
  65. Livingston M, Fraser IS. Mechanismen of abnormal uterine bleeding. Human Reprod Update (2002) 8: 60-67
  66. Hickey M et al.: Vaginal bleed ing disturbances and implantable contraceptives. Contraception 65 (2002) 75–84
  67. Hickey M et al.: Vaginal bleed ing disturbances and implantable contraceptives. Contraception 65 (2002) 75–84
  68. Pinkerton JV Menopause:2011; 18(4): 459-67
  69. Kaewrudee S et al.: The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception 60 (1999) 25–30
  70. Lethaby A, Farquhar C, Cooke I. Cochrane Database Syst Rev. (2000) 4:CD000249 Antifibrinolytics for heavy menstrual bleeding
  71. Wiegerinck MA, Poortman J, Donkeer TH, Thijssen JHH. In vivo uptake and subcellular distribution of tritium-labeled estrogens in human endometrium, mymometrium, and vagina. J Clin Endocr (1983) 56: 76-86
  72. Pasqualini JR, Chetrite GS. Recent advances on the action of estrogens and progestogens in normal and pathological human endometrium, Horm Mol Biol Invest (2010) 155-174
  73. Pasqualini JR, Chetrite GS. Recent advances on the action of estrogens and progestogens in normal and pathological human endometrium, Horm Mol Biol Invest (2010) 155-174
  74. Tseng LE. Gurpide E. Induction of human estradiol dehydrogenase by progestins. Endocrinology (1975) 97: 825-833
  75. Bolt HM, Göbel P. Ring A oxidation of 17a.ethinylestradiol in man. Hormon Metab Res (1974) 6: 432-433
  76. Bolt HM, Göbel P. Ring A oxidation of 17a.ethinylestradiol in man. Hormon Metab Res (1974) 6: 432-433
  77. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Europ J Contraception and Reproductive Health (2009) 14: 221.232
  78. Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest.Expert Opin Pharmacother (2010) 11: 1-11
  79. Micks E, Jensen JT. Estradiol valerate and dienogest: A novel four-phasic oral contraceptive pill effective for pregnancy prevention and heavy menstrual bleeding. Women's Health (2011) 7: 513-524
  80. Ahrendt J-J, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/ levonorgestrel. Contraception (2009) 80: 436-444
  81. Micks E, Jensen JT. Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and heavy menstrual bleeding. Women's Health 2011; 7: 513-524
  82. Bahamondes L, Bahamondes MV. Use of combined oral contraceptives for the management of heavy menstrual bleeding. Expert Rev Obstet Gynecol (2011) 6: 485-489
  83. Chabbert-Buffet N, Chassard D, Ochsenbein E, Thomas J-L, Christin-Maitre S. Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17poestradiol: A double-blind, randomised, dosefinding pilot study. Europ J Contraception and Reproductive Health (2011) Early online, 1-9
  84. Pasqualini JR, Chetrite GS. Recent advances on the action of estrogens and progestogens in normal and pathological human endometrium, Horm Mol Biol Invest (2010) 155-174
  85. Mueck AO, Sitruk-Ware R. Nomegestrol acetate, A novel progestogen for oral contraception. Steroids (2011) 76: 531-539
  86. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, Ochsenbein E, Chassard D, Thomas JL. Comparison of a 24 day and 21 day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17ß-estradiol: a doubleblind, randomized study. Human Reprod (2011) 26: 1338-1347
  87. Mueck AO, Seeger H, Bühling KJ. Why use of dienogest for the first contraceptive pill with estradiol. Gynecol Endocrinology (2010) 26:109-113
  88. Punnonen R, Söderström K-O. The effect of oral estriol succinate therapy on the endometrial morphology in postmenopausal women: the significance of fractionation of the dose. Europ J Obstet Gynecol Reprod Biol (1983) 14: 217-224
  89. Wren BG. Oestriol in the control of postmenopausal symptoms. Med J Aust (1982) 176-177
  90. Weichman B, Notides AC. Estrogen receptror activation and the dissociation kinetics of estradiol, estriol, and estrone. Endocrinology (1980) 106; 434-439
  91. Englund DE, Heimer G, Johansson EDB. Influence of food on oestriol blood levels. Maturitas (1984) 6: 71-75